SpringWorks Therapeutics Performance
| SWTXDelisted Stock | USD 46.99 0.00 0.00% |
The entity has a beta of -0.0913, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning SpringWorks Therapeutics are expected to decrease at a much lower rate. During the bear market, SpringWorks Therapeutics is likely to outperform the market. SpringWorks Therapeutics right now has a risk of 0.0%. Please validate SpringWorks Therapeutics maximum drawdown, skewness, market facilitation index, as well as the relationship between the downside variance and rate of daily change , to decide if SpringWorks Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days SpringWorks Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, SpringWorks Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
SpringWorks |
SpringWorks Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,699 in SpringWorks Therapeutics on September 28, 2025 and sell it today you would earn a total of 0.00 from holding SpringWorks Therapeutics or generate 0.0% return on investment over 90 days. SpringWorks Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than SpringWorks, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
SpringWorks Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SpringWorks Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SpringWorks Therapeutics, and traders can use it to determine the average amount a SpringWorks Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| SWTX |
Based on monthly moving average SpringWorks Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SpringWorks Therapeutics by adding SpringWorks Therapeutics to a well-diversified portfolio.
SpringWorks Therapeutics Fundamentals Growth
SpringWorks Stock prices reflect investors' perceptions of the future prospects and financial health of SpringWorks Therapeutics, and SpringWorks Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SpringWorks Stock performance.
| Return On Equity | -0.52 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (1.16) % | |||
| Operating Margin | (1.64) % | |||
| Current Valuation | 3.26 B | |||
| Shares Outstanding | 75.35 M | |||
| Price To Earning | 6.14 X | |||
| Price To Book | 8.49 X | |||
| Price To Sales | 16.12 X | |||
| Revenue | 191.59 M | |||
| EBITDA | (278.13 M) | |||
| Cash And Equivalents | 334.54 M | |||
| Cash Per Share | 6.81 X | |||
| Total Debt | 7.91 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 5.57 X | |||
| Cash Flow From Operations | (175.6 M) | |||
| Earnings Per Share | (3.41) X | |||
| Total Asset | 587.28 M | |||
| Retained Earnings | (1.15 B) | |||
| Current Asset | 29.13 M | |||
| Current Liabilities | 10.16 M | |||
About SpringWorks Therapeutics Performance
Evaluating SpringWorks Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if SpringWorks Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SpringWorks Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. Springworks Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.Things to note about SpringWorks Therapeutics performance evaluation
Checking the ongoing alerts about SpringWorks Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SpringWorks Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SpringWorks Therapeutics is not yet fully synchronised with the market data | |
| SpringWorks Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 191.59 M. Net Loss for the year was (258.13 M) with profit before overhead, payroll, taxes, and interest of 204.8 M. | |
| SpringWorks Therapeutics currently holds about 334.54 M in cash with (175.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.81. | |
| Over 87.0% of the company shares are owned by institutional investors |
- Analyzing SpringWorks Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SpringWorks Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining SpringWorks Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SpringWorks Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of SpringWorks Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SpringWorks Therapeutics' stock. These opinions can provide insight into SpringWorks Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in SpringWorks Stock
If you are still planning to invest in SpringWorks Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SpringWorks Therapeutics' history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |